Pfizer Corporation

Pfizer Products Inc.

John Michael Humphrey

Thomas Allen Chappie

Christopher John Helal

Patrick Robert Verhoest

Dennis J Hoover

Brian Thomas O'Neill

Arthur A Nagel

Spiros Liras

Martin Youngjin Pettersson

Douglas Scott Johnson

Norma Jacqueline Tom

Antonia Friederike Stepan

Christopher William Am Ende

Eddie Yang

Martin Patrick Allen

Lawrence Albert Vincent

Gregory Wayne Kauffman

Susan Beth Sobolov-Jaynes

Jianhua Huang

Eric Platt Arnold

Danica Antonia Rankic

William Michael Whalen

Dennis Jay Hoover

The present invention relates to compounds of the Formula 

Imidazo[5,1-f][1,2,4]triazines for the treatment of neurological disorders

The present invention provides, inter alia, compounds of Formula (I) and pharmaceutically acceptable salts thereof, to processes for the preparation of, intermediates used in the preparation of, and compositions containing such compounds and the uses of such compounds as a method for the treatment of a disease or condition selected from the group consisting of central nervous system disorders, cognitive disorders, schizophrenia, dementia and other disorders in a mammal. The present invention further provides compounds of Formula (Id) and pharmaceutically acceptable salts thereof as CYP3A4 selective inhibitors. 

[object Object]

The invention pertains to heteroaromatic compounds that serve as effective phosphodiesterase (PDE) inhibitors. In particular, the invention relates to said compounds which are selective inhibitors of PDE10. The invention also relates to intermediates for preparation of said compounds; pharmaceutical compositions comprising said compounds; and the use of said compounds in a method for treating certain central nervous system (CNS) or other disorders.

Heteroaromatic quinoline compounds

3-amino-2-phenylpyrrolidine compounds useful as NK-1 antagonists, with pharmaceutical compositions and methods of treatment comprising same, are disclosed.

3-amino-2-phenylpyrrolidine derivatives

The invention pertains to substituted quinazoline and isoquinoline compounds that serve as effective phosphodiesterase (PDE) inhibitors. In particular, the invention relates to said compounds which are selective inhibitors of PDE-10. The invention also relates to intermediates for preparation of said compounds; pharmaceutical compositions comprising said compounds; and the use of said compounds in a method for treating certain central nervous system (CNS) or other disorders.

Tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline

The present invention relates to certain benzoamide piperidine containing compounds and related compounds that exhibit activity as NK-1 receptor antagonists, (e.g., substance P receptor antagonists), to pharmaceutical compositions containing them, and to their use in the treatment and prevention of central nervous system disorders, inflammatory disorders, cardiovascular disorders, ophthalmic disorders, gastrointestinal disorders, disorders caused by, disorders of the immune system, urinary incontinence, pain, migraine, emesis, angiogenesis and other disorders.

Benzoamide piperidine containing compounds and related compounds

A process for interconverting a mixture of cis-trans isomers of a compound of formula I into the substantially pure cis isomer. Cis isomers of formula I are useful intermediates in the synthesis of cis isomers of benzamide piperidine compounds which exhibit activity as NK-1 receptor antagonists.

Process for converting a cis-trans mixture of substituted benzylidene amines into the pure cis isomer

Growing community of inventors

Mystic, CT, United States of America

John Michael Humphrey